Writing · Category

Psychedelics and Ketamine

I write about the research and the legal status of ketamine, esketamine, psilocybin and MDMA in psychiatry, including how each drug acts in the brain.

Esketamine vs Ketamine: How IV Ketamine and Spravato Compare

Esketamine vs Ketamine: What’s the Difference? If you’re weighing esketamine vs ketamine, you’re comparing two forms of the same medicine. IV ketamine is racemic ketamine, a 50/50 mix of two mirror-image forms of the molecule, given slowly through…

Read

How Many Ketamine Treatments for Depression? What the Trials Show

How Many Ketamine Treatments for Depression? In the main trials of IV ketamine for depression, a first series was 6 infusions over 2 to 3 weeks (Murrough et al., 2013; Anand et al., 2023). An expert panel recommends…

Read

How MDMA-Assisted Therapy Works, and Why the FDA Said No

Two phase 3 trials reported that MDMA-assisted therapy reduced severe PTSD symptoms more than the same therapy with an inactive pill. The improvements were large, the kind that usually carries a drug through to approval. In August 2024,…

Read

How Psilocybin Works in the Brain

Psilocybin doesn’t do much on its own. Your body converts it to psilocin, and psilocin switches on a single serotonin receptor in the cortex called 5-HT2A. Almost everything that follows starts there: the hallucinations, and the shift in…

Read

MKUltra: The CIA’s Psychedelic Experiments and Informed Consent

Between 1953 and the early 1970s, the Central Intelligence Agency ran experiments that gave powerful drugs to people who never agreed to take them. The program was called MKUltra. Its subjects included prisoners, psychiatric patients, people who used…

Read

The History of Psilocybin: From Ancient Ritual to the Modern Lab

The history of psilocybin is the longest and best documented of any psychedelic in medicine. That fact gets buried under a lot of vague language about ancient wisdom and sacred mushrooms. The real record is specific, and most…

Read

Psychedelics for Mental Health: What the 2026 Evidence Actually Shows

Published: April 2026 | Updated: October 2026 | By: Dr. Baghel | Category: Adult Psychiatry On April 18, 2026, President Trump signed a psychedelic therapy executive order directing federal agencies to accelerate research and access to psychedelic drugs…

Read